Loading clinical trials...

Addition of Homeopathy in Patients With Resistant Arterial Hypertension | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Addition of Homeopathy in Patients With Resistant Arterial Hypertension

Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Homeopathy in Resistant Arterial Hypertension

NCT02124473•Macmillan Research Group UK

Summary

Resistant hypertension (RHTN) is a common clinical problem faced by both primary care clinicians and specialists worldwide. Patients with RHTN have higher rates of cardiovascular events and mortality compared with patients with more easily controlled hypertension. In addition, RHTN is often complicated by metabolic abnormalities. Homeopathy, although widely used in hypertension, but no study has been taken to evaluate the impact on resistant hypertension. The aim of this trial was to evaluate individualized homeopathy on BP in patients with resistant hypertension.

Eligibility

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients older than 18 years with resistant arterial hypertension.
•Office systolic BP \>140 mm Hg or diastolic BP \>90 mm Hg despite being treated with at least 3 antihypertensive drugs, including a diuretic.
•Patients with diabetes or chronic kidney disease (defined as serum creatinine \>133 μmol/L or proteinuria \>300 mg/day) if the office BP was \>130/80 mm Hg.

Exclusion Criteria

•Severe hypertension (systolic BP \>180 mm Hg or diastolic BP \>110 mm Hg) who needed an immediate adjustment of treatment,
•Renal insufficiency with serum creatinine \>180 μmol/L or glomerular filtration rate \<40 mL/min calculated by the Modification of Diet in Renal Disease formula,15 hyperkalemia \>5.4 mmol/L, hyponatremia \<130 mmol/L, and porphyria;
•Pregnant or lactating women or women of fertile age not using effective contraception;
•Patients with known prior hypersensitivity to the drug Verospiron (spironolactone; Richter Gedeon Ltd) or who are currently using any aldosterone antagonist.

Locations (2)

NMP Medical Research Institute

Jaipur, Rajasthan, India

NMP Medical Research Institute

Jhunjhunūn, Rajasthan, India

Key Dates

Start Date

August 1, 2013

Primary Completion Date

January 1, 2014

Completion Date

March 1, 2014

Last Updated

April 28, 2014

Enrollment

ACTUAL participants

Conditions

Hypertension, Resistant to Conventional Therapy

Interventions

Homeopathy

OTHER

Placebo

OTHER

Baroloop Multicenter Trial (Baroloop MCT)

NCT06518915

Hypertension, Resistant to Conventional Therapy

View study

UNKNOWNNA

Moderato System in Patients With Hypertension

NCT03757377

Hypertension, Resistant to Conventional TherapyAtrioventricular Block

View study

COMPLETEDNA

Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 28, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions